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Abstract 
Background 
In several European Countries, by the end of 2012, CLSI guidelines will be replaced by 
EUCAST. We compared antimicrobial susceptibility results of a large number of respiratory 
pathogens using both EUCAST and previously adopted CLSI criteria to evaluate the impact 
on susceptibility patterns and the possible consequences that could occur in clinical practice 
due to this replacement. 
For S. pyogenes and S. aureus, the interpretation of susceptibility data using the EUCAST 
criteria did not produce relevant changes in comparison to CLSI. 
Against S. pneumoniae, more restrictive EUCAST breakpoints could lead to increased 
benzylpenicillin and/or amoxicillin-clavulanate resistance rates, which in turn could translate 
in increased dosages of these antibiotics or usage of alternative agents for respiratory tract 
infections. 
Against S. pneumoniae, M. catarrhalis and H. influenzae, cefuroxime-axetil and cefaclor 
produced the most divergent results depending on the breakpoints adopted and these striking 
differences could lead to the revision of those guidelines suggesting these two cephalosporins 
as alternatives in the management of upper respiratory tract infections. 
Discussion 
Many differences exist between CLSI and EUCAST breakpoints. However, only in a few 
cases do these differences translate in major interpretive category discrepancies. In countries 
adopting more restrictive EUCAST breakpoints, clinicians should be aware of these 
discrepancies and that they could be faced with antibiotic-resistant respiratory pathogens 
more frequently than before. 
Summary 
The interpretive discrepancies between EUCAST and CLSI suggest that the discussion on the 
management of community-acquired respiratory tract infections is still open and further 
studies are desirable to better define the role of some antibiotics. 
Keywords 
CLSI, Interpretive criteria, Resistance, Antibiotics, S. pneumoniae, H. influenzae, S. aureus, 
M. catarrhalis 
Background 
Acute community-acquired respiratory tract infections, including otitis media, sinusitis, 
exacerbations of chronic bronchitis, and community-acquired pneumonia, represent some of 
the most common infections treated by physicians [1]. 
The overall aetiology has not changed in recent years: Streptococcus pyogenes, S. 
pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are the most common 
pathogens. Infection with ‘atypical pathogens’ such as Mycoplasma pneumoniae, 
Chlamydiophila pneumoniae and Legionella pneumophila have also been reported [2,3]. As 
conjugate vaccines are introduced routinely, such as those against H. influenzae Type B and 
pneumococcus, they could change the aetiology of pneumonia, with “atypical pathogens” 
likely to become proportionally more important. In the community the management of these 
conditions is generally empirical [4-7] and recommendations on the most appropriate first-
line agents should also be based on updated local epidemiological data derived by the 
availability of antimicrobial susceptibility testing results, which in turn depend on 
interpretative criteria or ‘breakpoints’ used to divide a bacterial population into susceptible, 
intermediate and resistant categories. 
Because different agencies such as the CLSI (Clinical and Laboratory Standards Institute) 
and EUCAST (European Committee on Antimicrobial Susceptibility Testing) may suggest 
different breakpoints, the assignment of a pathogen to a defined category (susceptible, 
intermediate and resistant) depends on the specific guideline adopted. As a consequence, 
breakpoint discrepancies could have an important impact, possibly leading to divergent 
conclusions impinging on the selection of the drug to be used by the physician. 
Since in several European Countries, CLSI guidelines have been or are going to be replaced 
by EUCAST guidelines, we compared antimicrobial susceptibility results reported in 
literature on a large number of respiratory strains (mainly available at the EUCAST website) 
[8] using both EUCAST and previously adopted CLSI breakpoints to evaluate the impact of 
breakpoint changes on the overall susceptibility patterns and the possible consequences 
occurring in clinical practice. 
Methods 
Antimicrobial Susceptibility data (minimal inhibitory concentration distributions) obtained 
mainly from the EUCAST website [8] and from two published articles [9,10] were analysed 
using the latest available version of CLSI (Twenty-second Informational Supplement M100-
S22 and Methods for Antimicrobial Dilution and Disk Susceptibiltiy Testing of Infrequently 
Isolated or Fastidious Bacteria; Approved Guideline- Second Edition- M45-A2) [11,12] and 
EUCAST documents [13] breakpoints and were compared. 
It is worth noting that the percentages of susceptibility obtained cannot be used to assess 
susceptibility rates in any epidemiological context since, as already stated in the EUCAST 
website, susceptibility data were aggregated from different sources, countries and time 
periods. 
Only those antibiotic/pathogen combinations, for which both EUCAST and CLSI provide 
breakpoints, were included in the study, with the exception of S. pyogenes/chloramphenicol 
and S. aureus/netilmicin, due to the very limited number of minimal inhibitory concentration 
(MIC) values available for these two combinations. When, for each bacterial 
species/antibiotic combination, the percentages of susceptibility calculated by the two 
interpretive criteria (CLSI and EUCAST) differed by 0- < 1%, the results were considered 
comparable. 
Discrepancies were arbitrarily defined as follows: minor discrepancies as differences ranging 
between 1 and 10% (1- < 10%), major discrepancies as differences ranging between 10 and 
25% (10- < 25%) and very major discrepancies as differences greater than or equal to 25% 
(≥25%). 
Results 
Table 1 reports the antimicrobial susceptibilities of S. pyogenes isolates to six antimicrobial 
agents, according to the available CLSI and EUCAST interpretive breakpoints. 
Table 1 Antimicrobial susceptibility of S. pyogenes as classified by CLSI and EUCAST § 
Antimicrobial agent
a
 
(n° of strains) 
CLSI 
susceptibility 
breakpoint 
(mg/L) 
EUCAST 
susceptibility 
breakpoint 
(mg/L) 
CLSI 
%S 
EUCAST 
%S 
Type of 
discrepancy 
b
 
Penicillin (934) ≤0.12 ≤0.25 99.9 100 - 
Azithromycin (22.884) ≤0.5 ≤0.25 91.7 91.2 - 
Clindamycin (10.994) ≤0.25 ≤0.5 96.6 96.7 - 
Levofloxacin (26.775) ≤2 ≤1 99.0 93.1 minor 
Vancomycin (10.728) ≤1 ≤2 100 100 - 
Tetracycline (2.413) ≤2 ≤1 83.9 83.7 - 
§ CLSI [11] and EUCAST [13] 
A
For Erythromycin, Clarithromycin, Linezolid and Daptomycin CLSI and EUCAST 
suggested the same susceptibility breakpoints 
b
 Discrepancy as defined in the materials and methods section 
Globally, the susceptibility rates calculated following the two guidelines appear to be 
identical or very similar (<1%), with the exception of levofloxacin. Using the CLSI 
breakpoint, the percentage of levofloxacin susceptible isolates was lower than that obtained 
following the EUCAST criteria (99.0% vs 93.1% respectively), leading to a minor 
discrepancy. 
Comparable results or minor discrepancies were observed for the great majority of antibiotics 
studied against S. pneumoniae (Table 2). However, adoption of the more restrictive EUCAST 
breakpoints for cefaclor and ofloxacin produced very major discrepancies. Using the 
EUCAST breakpoints, the percentage of cefaclor and ofloxacin susceptible strains was 
drastically reduced (<1%) in comparison to CLSI results (>90% of susceptibile strains). For 
other beta-lactams the adoption of EUCAST breakpoints caused a reduction in the 
percentages of susceptible strains leading to minor (penicillin, cefpodoxime, cefuroxime 
axetil, cefotaxime, ceftriaxone, meropenem and imipenem) and major discrepancies 
(amoxicillin-clavulanate), when compared with CLSI results. 
Table 2 Antimicrobial susceptibility of S. pneumoniae as classified by CLSI and 
EUCAST § 
Antimicrobial agent 
a
 
(n° of strains) 
CLSI 
susceptibility 
breakpoint 
(mg/L) 
EUCAST 
susceptibility 
breakpoint 
(mg/L) 
CLSI 
%S 
EUCAST 
%S 
Type of 
discrepancy 
b
 
Benzyl-penicillin 
(37.642) 
≤2*c ≤1** 94.2 87.4 minor 
Amoxicillin-clavulanate 
(2725) 
≤2 ≤0.5*** 99.2 87.6 major 
Cefaclor (2.581) ≤1 ≤0.032 92.3 0.5 very major 
Cefpodoxime (5.725) ≤0.5 ≤0.25 84.1 82.5 minor 
Cefuroxime axetil 
(32.729) 
≤1 ≤0.25 79.6 73.6 minor 
Cefotaxime (12.800) ≤1c ≤0.5 99.3 97.6 minor 
Ceftriaxone (3.138) ≤1c ≤0.5 98.4 89.7 minor 
Meropenem (575) ≤0.25c ≤2 97.7 99.8 minor 
Ertapenem (3.680) ≤1 ≤0.5 99.7 99.0 - 
Imipenem (1.643) ≤0.12 ≤2 95.4 99.9 minor 
Moxifloxacin (26.746) ≤1 ≤0.5 98.5 98.4 - 
Ofloxacin (4.412) ≤2 ≤0.125 95.4 0.0 very major 
Azithromycin (63.481) ≤0.5 ≤0.25 69.1 68.8 - 
Telithromycin (7.034) ≤1 ≤0.25 99.4 95.9 minor 
Clindamycin (38.126) ≤0.25 ≤0.5 81.4 81.6 - 
Vancomycin (51.053) ≤1 ≤2 99.8 100 - 
§ CLSI [11] and EUCAST [13] 
a
For Cefuroxime parenteral, Levofloxacin, Erythromycin and Clarithromycin, CLSI and 
EUCAST suggested the same susceptibility breakpoints. 
b
Discrepancy as defined in the materials and methods section 
c
Breakpoint refers to non meningeal infections 
* breakpoint refers to a dosage of 2 million units 6 times daily 
** breakpoint refers to a dosage of 2.4 gm 4 times or 1.2 gm 6 times daily 
*** breakpoint refers to Ampicillin. The rate of susceptibiliy to Amoxicillin-clavulanate has 
been inferred from the rate of susceptibility to Ampicillin 
With regard to H. influenzae, no relevant differences were observed for 7 out of the 21 
compared antimicrobial agents (Table 3). Among the beta-lactams, oral cephalosporins, 
cefaclor and cefuroxime-axetil were those producing the most divergent results depending on 
the breakpoints adopted. Similarly, for azithromycin clarithromycin and telithromycin, while 
high percentages of susceptible isolates (>99%, 82.9% and >98% respectively) were obtained 
when adopting CLSI breakpoints, less than 2% of the strains were susceptible when results 
were interpreted according to EUCAST breakpoints). 
Table 3 Antimicrobial susceptibility of H. influenzae as classified by CLSI and EUCAST § 
Antimicrobial agent 
a
 
(n° of strains) 
CLSI 
susceptibility 
breakpoint 
(mg/L) 
EUCAST 
susceptibility 
breakpoint 
(mg/L) 
CLSI 
%S 
EUCAST 
%S 
Type of 
discrepancy 
b
 
Ampicillin-sulbactam 
(223) 
≤2 ≤1 98.2 92.4 minor 
Amoxicillin-clavulanate 
(47.030) 
≤4 ≤2 99.7 98.4 minor 
Cefaclor (28.338) ≤8 ≤0.5 92.6 3.5 very major 
Cefixime (7.403) ≤1 ≤0.125 99.9 97.9 minor 
Cefpodoxime (20.842) ≤2 ≤0.25 99.9 96.7 minor 
Cefuroxime axetil 
(94.671) 
≤4 ≤0.125 97.9 1.3 very major 
Cefuroxime parenteral 
(94.671) 
≤4 ≤1 97.9 76.9 major 
Cefotaxime (13.655) ≤2 ≤0.125 99.6 99.7 - 
Ceftriaxone (170) ≤2 ≤0.125 100 96.5 minor 
Cefepime (396) ≤2 ≤0.25 100 91.7 minor 
Ceftibuten (444) ≤2 ≤1 98.4 97.1 minor 
Meropenem non 
meningitis (6.511) 
≤0.5 ≤2 99.9 100 - 
Imipenem (3.828) ≤4 ≤2 98.9 97.4 minor 
Ciprofloxacin (12.794) ≤1 ≤0.5 99.7 99.6 - 
Levofloxacin (22.880) ≤2 ≤1 99.9 99.8 - 
Moxifloxacin (14.177) ≤1 ≤0.5 99.7 99.8 - 
Ofloxacin (3.762) ≤2 ≤0.5 100 99.9 - 
Azithromycin (29.942) ≤4 ≤0.125 99.3 1.2 very major 
Clarithromycin (27.816) ≤8 ≤1 82.9 1.5 very major 
Telithromycin (5.382) ≤4 ≤0.125 99.0 0.5 very major 
Tetracycline (39.928) ≤2 ≤1 97.7 96.8 - 
§ CLSI [11] and EUCAST [13] 
a
For Ampicillin, Chloramphenicol, Ertapenem, Rifampin and 
Trimethoprim/sulfamethoxazole CLSI and EUCAST suggested the same susceptibility 
breakpoints. 
b
 Discrepancy as defined in the materials and methods section 
Concerning M. catarrhalis, very major discrepancies, due to the adoption of different 
breakpoints on calculated susceptibility percentages, were only seen with cefaclor and 
cefuroxime-axetil (Table 4). Cefaclor and cefuroxime-axetil susceptibility percentages were 
dramatically reduced using EUCAST breakpoints (<2% vs 95.1% and 98.7% of susceptible 
strains when adopting CLSI criteria). 
Table 4 Antimicrobial susceptibility of M. catarrhalis as classified by CLSI and 
EUCAST § 
Antimicrobial agent 
a
 
(n° of strains) 
CLSI 
susceptibility 
breakpoint 
(mg/L) 
EUCAST 
susceptibility 
breakpoint 
(mg/L) 
CLSI 
%S 
EUCAST 
%S 
Type of 
discrepancy 
b
 
Amoxicillin-clavulanate 
(3.549) 
≤4 ≤1 100 99.9 - 
Cefaclor (7.536) ≤8 ≤0.12 95.1 0.27 very major 
Cefuroxime axetil 
(15.381) 
≤4 ≤0.125 98.7 1.2 very major 
Cefotaxime (2.737) ≤2 ≤1 99.9 99.6 - 
Ceftriaxone (5.187) ≤2 ≤1 99.9 99.1 - 
Clarithromycin (910) ≤1 ≤0.25 100 99.9 - 
Erythromycin (3.038) ≤2 ≤0.25 100 99.7 - 
Ciprofloxacin (11.119) ≤1 ≤0.5 99.9 99.9 - 
Levofloxacin (5.239) ≤2 ≤1 100 99.9 - 
Tetracycline (8.660) ≤2 ≤1 97.7 94.8 - 
§ CLSI [11] and EUCAST [13] 
a
For Chloramphenicol and Trimethoprim/sulfamethoxazole CLSI and EUCAST suggested 
the same susceptibility breakpoints. 
b
 Discrepancy as defined in the materials and methods section 
Regarding S. aureus, only minor discrepancies were detected between the susceptibility rates 
calculated using EUCAST and CLSI breakpoints for all compared antibiotics (Table 5). 
Table 5 Antimicrobial susceptibility of S. aureus as classified by CLSI and EUCAST § 
Antimicrobial agent 
a
 
(n° of strains) 
CLSI 
susceptibility 
breakpoint 
(mg/L) 
EUCAST 
susceptibility 
breakpoint 
(mg/L) 
CLSI 
%S 
EUCAST 
%S 
Type of 
discrepancy 
b
 
Teicoplanin (56.399) ≤8 ≤2 99.9 98.4 minor 
Gentamicin (45.807) ≤4 ≤1 93.6 89.1 minor 
Amikacin (6.446) ≤16 ≤8 97.6 92.6 minor 
Tobramycin (3.155) ≤4 ≤1 94.7 88.2 minor 
Azithromycin (7.223) ≤2 ≤1 58.6 56.2 minor 
Clarithromycin (7.146) ≤2 ≤1 58.8 58.5 - 
Erytromycin (36.118) ≤0.5 ≤2 74.8 77.4 minor 
Tetracycline (1.864) ≤4 ≤1 74.6 74.3 - 
Doxycycline (5.037) ≤4 ≤1 97.6 88.7 minor 
Minocycline (1.417) ≤4 ≤0.5 99.4 96.9 minor 
Clindamycin (25.879) ≤0.5 ≤0.25 87.5 87.2 - 
Trimethoprim (449) ≤8 ≤2 91.5 89.1 minor 
Rifampin (1.154) ≤1 ≤0.064 96.4 95.0 minor 
§ CLSI [11] and EUCAST [13] 
a
 For Penicillin, Oxacillin, Vancomycin, Daptomycin, Ciprofloxacin, Levofloxacin, 
Ofloxacin, Moxifloxacin, Chloramphenicol, Trimethoprim-sulfamethoxazole, Quinupristin-
dalfopristin and Linezolid CLSI and EUCAST suggested the same susceptibility breakpoints. 
b
 Discrepancy as defined in the materials and methods section 
Major categorical shift, percentages of intermediate and resistant strains for S. pneumoniae, 
H. influenzae and M. catarrhalis are detailed in Table 6. 
Table 6 Pathogen/antibiotic combinations that present major changes and potential therapeutic consequences 
Pathogen/antibiotic CLSI 
%S 
CLSI 
% I 
CLSI 
% R 
EUCAST 
%S 
EUCAST 
% I 
EUCAST 
% R 
Major 
categorical 
shift 
Potential 
therapeutic 
consequences 
Possible alternative/s 
S. pneumoniae/          
Amoxicillin-
clavulanate  
(2568) 
95.6 
(2457) 
4.3 
(110) 
0.1 
(2) 
73.4 
(1884) 
13.9 
(358) 
12.7 
(326) 
S→I/R Reduced or no 
efficacy 
Increased dosage of amoxicillin-
clavulanate 
Cefaclor  
(2581) 
92.3 
(2384) 
1.7 
(45) 
5.9 
(152) 
0.5 
(13) 
86.7 
(2238) 
13 
(330) 
S→I/R Reduced or no 
efficacy 
Other oral cephalosporin/high 
dosage of amoxicillin-clavulanate 
Ofloxacin  
(4412) 
95.4 
(4208) 
4.3 
(190) 
0.3 
(14) 
0.0 99.5 
(4388) 
0.3 
(14) 
S→I Reduced efficacy Fluoroquinolones (moxifloxacin, 
levofloxacin, gemifloxacin) 
H. influenzae/          
Cefaclor  
(28338) 
92.6 
(26337) 
5.2 
(1481) 
2.3 
(654) 
3.5 
(990) 
/ 96.5 
(27482) 
S→R No efficacy Other cephalosporin/amoxicillin-
clavulanate 
Cefuroxime-axetil 
(94671) 
97.9 
(92668) 
1.5 
(1390) 
0.6 
(613) 
1.3  
(1249) 
75.6 
(71574) 
23.1 
(21848) 
S→I/R Reduced or no 
efficacy 
Other cephalosporin/amoxicillin-
clavulanate 
Cefuroxime- 
parenteral 
(94671) 
97.9 
(92668) 
1.5 
(1390) 
0.6 
(613) 
76.9 
(72823) 
10.5 
(9963) 
12.6 
(11885) 
S→ I/R Reduced or no 
efficacy 
Other cephalosporin/amoxicillin-
clavulanate 
Azithromycin 
(29942) 
99.3 
(29733) 
/ / 1.2 
(350) 
98.1 
(29383) 
0.7  
(209) 
S→I Reduced or no 
efficacy 
Betalactam/fluoroquinolones 
Clarithromycin 
(27816) 
82.9 
(23045) 
15.3 
(4257) 
1.8 
(514) 
1.5  
(424) 
98.1 
(27296) 
0.3  
(96) 
S→I Reduced or no 
efficacy 
Betalactam/fluoroquinolones 
Telithromycin  
(5382) 
89.9 
(4837) 
9.0 
(486) 
1.1 
(59) 
0.5  
(26) 
99.1 
(5335) 
0.4  
(21) 
S→I Reduced or no 
efficacy 
Betalactam/fluoroquinolones 
M. catarrhalis/          
Cefaclor  
(7536) 
95.1 
(7163) 
3.4 
(253) 
1.6 
(120) 
0.27  
(21) 
/ 99.7 
(7515) 
S→R No efficacy Other cephalosporin/amoxicillin-
clavulanate 
Cefuroxime-axetil 
(15381) 
98.7 
(15183) 
1.1 
(175) 
0.1 
(23) 
1.2  
(189) 
97.5 
(14994) 
1.3 (198) S→I/R Reduced or no 
efficacy 
Other cephalosporin/amoxicillin-
clavulanate 
S. pneumoniae CLSI 2012 intermediate breakpoint (mg/L) amoxicillin-clavulanate 4/2, cefaclor 2, ofloxacin 4; EUCAST 2012 intermediate breakpoint 
(mg/L) amoxicillin-clavulanate 1–2, cefaclor 0.06-0.5, ofloxacin 0.25-4; CLSI 2012 resistance breakpoint (mg/L) amoxicillin-clavulanate ≥8/4, cefaclor ≥4, 
ofloxacin ≥8; EUCAST 2012 resistance breakpoint (mg/L) amoxicillin-clavulanate >2, cefaclor >0.5, ofloxacin >4 
H. influenzae CLSI 2012 intermediate breakpoint (mg/L) cefaclor 16, cefuroxime axetil 8, cefuroxime parenteral 8, azithromycin ND, clarithromycin 16, 
telithromycin 4; EUCAST 2012 intermediate breakpoint (mg/L) cefaclor ND, cefuroxime axetil 0.25-1, cefuroxime parenteral 2, azithromycin 0.25-4, 
clarithromycin 2–32, telithromycin 0.25-8; CLSI 2012 resistance breakpoint (mg/L) cefaclor ≥32, cefuroxime axetil ≥16, cefuroxime parenteral ≥16, 
azithromycin ND, clarithromycin ≥32, telithromycin ≥8; EUCAST 2012 resistance breakpoint (mg/L) cefaclor >0.5, cefuroxime axetil >1, cefuroxime 
parenteral >2, azithromycin >4, clarithromycin >32, telithromycin >8 
M. catarrhalis CLSI 2012 intermediate breakpoint (mg/L) cefaclor 16, cefuroxime axetil 8; EUCAST 2012 intermediate breakpoint (mg/L) cefaclor ND, 
cefuroxime axetil 0.25-4; 
CLSI 2012 resistance breakpoint (mg/L) cefaclor ≥32, cefuroxime axetil ≥16; EUCAST 2012 resistance breakpoint (mg/L) cefaclor >0.12, cefuroxime axetil 
>4 
Discussion 
During last two decades the emergence and spread of resistance to several antimicrobial 
agents in the most common respiratory pathogens has been observed worldwide [14-16]. 
Classification of susceptibility/resistance depends on the breakpoints that are used routinely 
in the clinical laboratory and that influence clinical decision-making. However, these 
breakpoints vary over time and due to differing guidelines. Hence, the importance of 
maintaining a database of raw MIC values rather than categorical reports from laboratories to 
track resistance trends. 
CLSI, the most widely used guideline, has based preliminary breakpoints on MIC 
distributions, pharmacokinetic–pharmacodynamic (PK–PD) parameters and mechanisms of 
antimicrobial resistance. These suggestions were later confirmed in clinical trials [17]. 
Modern principles and methodologies are now utilized to evaluate the PK–PD of 
antimicrobials. EUCAST uses PK–PD simulations as a chief component of its breakpoint-
setting process for old and new antimicrobials [18,19]. 
Due to these differences, CLSI and EUCAST breakpoints are widely divergent in several 
instances and the adoption of CLSI or EUCAST interpretive criteria may therefore lead to 
different results and conclusions. 
In this study, we have compared the susceptibility data calculated using both EUCAST and 
CLSI breakpoints for large numbers of respiratory pathogens collected during several 
national and international studies to discuss the implications, if any, for empiric therapy of 
patients to be treated for community-acquired respiratory infections. 
Concerning S. pyogenes, a number of antibiotics have been shown to be effective in treating 
group A streptococcal pharyngitis. Penicillin, however, remains the treatment of choice 
because of its proven efficacy and safety, and its narrow spectrum and low cost [4]. 
To date no strain of penicillin-resistant S. pyogenes has been described worldwide and the 
adoption of the EUCAST susceptibility breakpoint (0.25 mg/L) which is even less restrictive 
than CLSI (0.12 mg/L) does not change the present scenario. 
Macrolides are a suitable alternative for patients allergic to penicillin. However, macrolides 
have often been incorrectly used as first-line agents, leading to high rates of macrolide 
resistance [20]. For the patient infected with an erythromycin-resistant strain of S. pyogenes 
and unable to tolerate β-lactam antibiotics, clindamycin is an appropriate alternative, in those 
countries where cross-resistance involving macrolides, lincosamides and streptogramins is 
not widespread. Using EUCAST breakpoints, the percentages of macrolides and clindamycin 
susceptible isolates were very similar to those obtained following CLSI criteria and no 
relevant discrepancies were observed. 
Fluoroquinolone-resistant S. pyogenes strains are becoming a common finding both in adult 
and paediatric patients [21-23] and the adoption of EUCAST breakpoints, more restrictive 
than CLSI for levofloxacin, can contribute to further increase the rates of levofloxacin-
resistant strains observed. However, respiratory fluoroquinolones are not yet recommended 
for respiratory infections due to S. pyogenes and, at present, replacing CLSI with EUCAST 
breakpoints can produce relevant changes only for epidemiological studies. 
During the last two decades, surveillance studies continued to reveal increasing resistance of 
S. pneumoniae, the leading cause of pneumonia, otitis media and rhinosinusitis, to a variety 
of antimicrobial agents, including first line agents beta-lactams, macrolides, and quinolones 
[14-16]. 
EUCAST and CLSI benzylpenicillin breakpoints for S. pneumoniae are both in relation to the 
dosage. Comparing breakpoints referring to a similar dosage (2.4 gm 4 times or 1.2 gm 6 
times daily for EUCAST and 2 million units 6 times daily for CLSI) EUCAST susceptibility 
breakpoint (≤1 mg/L) was more restrictive than CLSI breakpoint (≤2 mg/L) and higher 
dosages are suggested by EUCAST (2.4 gm 6 times daily) to cope with pneumococcal strains 
displaying a benzylpenicillin MIC of 2 mg/L. However, it has been shown that there is no 
relationship between mortality and penicillin MIC ≥ 2 mg/L and the CLSI suggest that 
intermediate strains (4 mg/L) may require penicillin dosages of 18 to 24 million units [24]. 
In contrast to CLSI, EUCAST did not publish specific breakpoints for amoxicillin or 
amoxicillin-clavulanate, the first line agents for otitis media and rhinosinusitis. For both 
agencies, isolates fully susceptible to benzylpenicillin can be reported as susceptible to 
amoxicillin (with or without a beta-lactamase inhibitor), otherwise EUCAST suggests using 
ampicillin to categorize susceptibility to amoxicillin and amoxicillin-clavulanate. 
Most MIC values for penicillin, ampicillin and amoxicillin differ by no more than one 
dilution step and several studies have shown that amoxicillin MICs are lower than the MICs 
of penicillin and/or ampicillin [9]. Since the EUCAST ampicillin breakpoint for susceptibility 
is ≤ 0.5 mg/L and the CLSI breakpoint for amoxicillin is ≤2 mg/L, the EUCAST breakpoint is 
once again more restrictive than the CLSI. In those countries, such as Italy, where CLSI 
criteria will be replaced by EUCAST criteria, higher rates of penicillin and amoxicillin 
resistance are to be expected. The more restrictive EUCAST approach, on the one hand 
reduces the risk of discordant therapy, but on the other hand it could have a detrimental 
ecological consequence due to use of alternative agents such as fluoroquinolones, further 
increasing the burden of antimicrobial selective pressure. 
Concerning the other beta-lactams, the most divergent results were seen with cefaclor. Based 
on PK/PD considerations, the EUCAST breakpoints for cefaclor (0.032/0.5 mg/L) have been 
set to ensure that the wild type is reported intermediate, indicating the need for high dosage to 
treat infections with wild type isolates, and any isolates with raised MICs are considered 
resistant. 
The adoption of EUCAST breakpoints for S. pneumoniae has limited or no impact on the 
activity of macrolides and fluoroquinolones, with the exception of ofloxacin. The EUCAST 
breakpoints for ofloxacin (0.125/4 mg/L) have been set to ensure that the wild type is 
reported intermediate, indicating the need for high dosage to treat infections with wild type 
isolates, and any isolates with raised MICs are considered resistant. Ciprofloxacin and 
ofloxacin (being first on the market) were approved for pneumococcal infections. However, 
since respiratory fluoroquinolones with enhanced activity against S. pneumoniae 
(levofloxacin, moxifloxacin or gemifloxacin) have become available, they have replaced 
second generation fluoroquinolones (ofloxacin or ciprofloxacin) in the guidelines [5,6]. 
M. catarrhalis and H. influenzae are implicated in a significant proportion of cases of acute 
exacerbations of chronic bronchitis, acute bacterial otitis, acute bacterial rhinosinusitis and 
seem to also have a role in community-acquired pneumonia [25,26]. The main resistance 
problem related to these two pathogens is the production of beta-lactamase (penicillinase). 
Rates for penicillinase producers reaches >80% in M. catarrhalis worldwide, and varies 
considerably with the geographic area for H. influenzae [15], but with the exception of 
penicllin and aminopenicillins, other molecules retain a good activity against these species. 
EUCAST ampicillin-sulbactam, amoxicillin-clavulanate and cefuroxime (parenteral use) 
breakpoints are lower than those suggested by CLSI and higher rates are expected following 
the introduction of EUCAST breakpoints. EUCAST breakpoints for cefuroxime axetil and 
cefaclor, based on PK/PD breakpoints, are 4- and 5-fold dilution lower than those of CLSI 
respectively and this shift translated into major and very major discrepancies when 
percentages of susceptible strains were calculated using the two criteria. According to CLSI 
breakpoints 98% and 99% of M. catarrhalis and H. influenzae were susceptible to 
cefuroxime axetil respectively, while with the adoption of EUCAST breakpoints the majority 
of the strains (>98%) were categorized as intermediate or resistant. A similar shift was 
observed for H. influenzae, M. catarrhalis and cefaclor. 
The adoption of EUCAST criteria for H. influenzae produced very major discrepancies for 
macrolides when the rates of susceptibility calculated using EUCAST and CLSI breakpoints 
were compared, as breakpoints for macrolides and related antibiotics have been set by 
EUCAST to categorize wild type H. influenzae as intermediate. The impact of this 
discrepancy should be limited on empirical therapy, since it is already well known that the 
correlation between macrolide MICs and clinical outcome is weak due to pharmacokinetic 
limitations [27]. 
S. aureus causes community-acquired respiratory tract infections less frequently than S. 
pneumoniae, H. influenzae and M. catarrhalis, but it is particularly implicated in community-
acquired infections in elderly patients [28]. Methicillin-resistant S. aureus (MRSA) can be 
resistant to multiple antimicrobials compromising the utility of many currently licensed 
antimicrobials. The replacement of CLSI with EUCAST breakpoints did not produce relevant 
changes for all the comparable antibiotics, including oxacillin and cefoxitin, thus no 
difference in MRSA rates are to be expected. 
While the limited discrepancies observed for S. pyogenes are not expected to have a clinical 
impact on the therapeutic choice for pharyngotonsillitis, higher rates of penicillin, amoxicillin 
and amoxicillin-clavualante resistance in S. pneumoniae could translate in increasing dosages 
of these agents or increasing use of alternative drugs as suggested by national and 
international guidelines to treat respiratory tract infections. 
Cefaclor and/or cefuroxime axetil, when adopting EUCAST breakpoints, have reduced in 
vitro activity against S. pneumoniae, H. influenzae and M. catarrhalis in comparison to CLSI. 
This observation could lead to promote further clinical studies to better define the role of 
these antibiotics and/or to the revision of those guidelines suggesting these molecules as 
alternative antimicrobial agents for upper respiratory tract infections both in adults and 
paediatric patients [29-33]. 
A possible limitation of our study is the heterogeneous source of the MIC data. However, we 
analysed a very large number of strains and the discrepancies highlighted here (only major 
and very major) are likely the result of EUCAST breakpoint changes, rendering all wild-type 
microorganisms intermediate or resistant to the specific antibiotic studied. 
In Countries, where EUCAST breakpoints are going to be adopted, clinicians should be 
aware that they could be faced with antibiotic-resistant respiratory pathogens more frequently 
than before. However, the susceptibility results provided by the microbiology laboratory, 
according to the EUCAST Committee should be more consistent with pharmacokinetic–
pharmacodynamic data and clinical evidence reported in literature. 
If the CLSI revises it breakpoints, making them as restrictive as those suggested by 
EUCAST, the changes highlighted in the present work and the possible revision of guidelines 
for the management of respiratory tract infections will also be expected in those countries 
adopting CLSI interpretive criteria. 
Summary 
• In European countries CLSI breakpoints are going to be replaced with those published 
by EUCAST. 
• As there are many differences between the CLSI and EUCAST breakpoints, we 
discuss the impact of this replacement on the overall susceptibility and the possible 
consequences occurring in clinical practice. 
• With rare exception, for the majority of pathogen/antibiotic combinations the impact 
is limited. 
• For these exceptions, we recommend that further clinical studies are promoted to 
better define the clinical role of some antibiotics. 
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